Literature DB >> 3875319

Involvement of complement in psoriasis and atopic dermatitis--measurement of C3a and C5a, C3, C4 and C1 inactivator.

A Kapp, H Wokalek, E Schöpf.   

Abstract

Normal complement components and activation products were determined in the peripheral blood of 35 patients with atopic dermatitis (AD) and 24 patients with psoriasis at a mild to intermediate stage. None of the patients had received systemic or local steroid therapy 6 weeks prior to blood collection. Levels of C3, C4 and C1 inactivator (C1 INA) were determined in serum by radial immunodiffusion, whereas C3a and C5a levels were measured by radioimmunoassay. In comparison to healthy non-atopic controls, the levels of C3, C4 and C1 INA were found to be significantly increased in both diseases. No substantial differences were detected between patients with psoriasis vulgaris and psoriasis guttata, which suggests that the dissimilarities found were not due to preceding or concomitant infections. In AD, there was a tendency towards increased C3a levels, whereas in psoriasis, C3a levels were significantly increased. In both diseases, no measurable amounts of C5a could be detected. The results indicate that, in both AD and psoriasis, the complement participates in the inflammatory process. Elevated levels of C3a suggest that there is a continuous activation of the complement system leading to the generation of inflammatory mediators.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3875319     DOI: 10.1007/bf00509233

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  13 in total

1.  Serum complement (beta 1C) in young children with atopic dermatitis.

Authors:  H S Kaufman; O L Frick; D Fink
Journal:  J Allergy       Date:  1968-07

2.  Demonstration of C3 cleavage product in leukotactic substances of scale extract from pustular psoriasis.

Authors:  H Tagami; S Ofuji
Journal:  Br J Dermatol       Date:  1977-01       Impact factor: 9.302

Review 3.  Synthesis of complement by macrophages and modulation of their functions through complement activation.

Authors:  H P Hartung; U Hadding
Journal:  Springer Semin Immunopathol       Date:  1983

4.  Influence of time, temperature and coagulation on the measurement of C3, C3 split products and C4.

Authors:  M J Sinosich; B Teisner; I Brandslund; M Fisher; J G Grudzinskas
Journal:  J Immunol Methods       Date:  1982-11-26       Impact factor: 2.303

5.  Complexed IgE in atopy.

Authors:  J Brostoff; P Johns; D R Stanworth
Journal:  Lancet       Date:  1977-10-08       Impact factor: 79.321

6.  Immunoglobulin, complement and fibrinolytic enzyme system in atopic dermatitis.

Authors:  K Yamamoto
Journal:  Mod Probl Paediatr       Date:  1975

7.  [Demonstration of circulating soluble immune complexes in the sera of psoriatic patients using the 125I-C1q deviation test].

Authors:  O Braun-Falco; C Männel; R Scherer
Journal:  Hautarzt       Date:  1977-12       Impact factor: 0.751

8.  Characterization of a leukotactic factor derived from psoriatic scale.

Authors:  H Tagami; S Ofuji
Journal:  Br J Dermatol       Date:  1977-11       Impact factor: 9.302

9.  Circulating IgA immune complexes in patients with psoriasis.

Authors:  R P Hall; G L Peck; T J Lawley
Journal:  J Invest Dermatol       Date:  1983-06       Impact factor: 8.551

10.  Serum immunoglobulin and complement levels in patients with psoriasis vulgaris.

Authors:  V Kikindjanin; J Milakov
Journal:  Allerg Immunol (Leipz)       Date:  1976
View more
  6 in total

1.  Defective monocyte and polymorphonuclear leukocyte chemotaxis and clinical characteristics in atopic dermatitis.

Authors:  T Ternowitz; T Herlin
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

2.  Neutrophil locomotion and serum chemotactic and chemokinetic activities in pustulosis palmoplantaris compared with psoriasis.

Authors:  A Lundin; L Håkansson; G Michaëlsson; P Venge
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

3.  Human monocyte-derived dendritic cells are chemoattracted to C3a after up-regulation of the C3a receptor with interferons.

Authors:  Ralf Gutzmer; Margarete Lisewski; Jörg Zwirner; Susanne Mommert; Carola Diesel; Miriam Wittmann; Alexander Kapp; Thomas Werfel
Journal:  Immunology       Date:  2004-04       Impact factor: 7.397

Review 4.  Complement Activation in Inflammatory Skin Diseases.

Authors:  Jenny Giang; Marc A J Seelen; Martijn B A van Doorn; Robert Rissmann; Errol P Prens; Jeffrey Damman
Journal:  Front Immunol       Date:  2018-04-16       Impact factor: 7.561

5.  C5a/C5aR1 Pathway Is Critical for the Pathogenesis of Psoriasis.

Authors:  Quan-You Zheng; Shen-Ju Liang; Feng Xu; Gui-Qing Li; Na Luo; Shun Wu; You Li; Ming Tang; Yu Zhong; Jian Chen; Di Yang; Dao-Dong Sun; Ke-Qin Zhang; Gui-Lian Xu
Journal:  Front Immunol       Date:  2019-08-07       Impact factor: 7.561

6.  C3a is required for ILC2 function in allergic airway inflammation.

Authors:  Naina Gour; Ursula Smole; Hwan-Mee Yong; Ian P Lewkowich; Nu Yao; Anju Singh; Edward Gabrielson; Marsha Wills-Karp; Stephane Lajoie
Journal:  Mucosal Immunol       Date:  2018-08-13       Impact factor: 7.313

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.